Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Seagen, a wholly owned subsidiary of Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed UC originating from the renal pelvis, ureters, bladder, or urethra. Mixed-cell type tumors are eligible as long as urothelial cell carcinoma is the predominant cell type.
Locally advanced unresectable or metastatic stage disease
Formalin fixed paraffin embedded (FFPE) tumor tissue blocks (or freshly sectioned slides, see laboratory manual for details) available for HER2 testing.
At least 1 prior line of systemic therapy for locally advanced unresectable or metastatic urothelial carcinoma (LA/mUC), including 1 line of platinum-containing chemotherapy.
Initiation of anticancer therapy for UC after prior progression on platinum-based therapy with or without maintenance avelumab between 01 January 2019 and 12 months before the end of data collection
Radiographically documented and measurable disease progression immediately before index date
You may not be if
Any concurrent malignant neoplasm requiring systemic therapy during the study window
Enrollment in a therapeutic clinical trial and received non-standard of care treatment during index line of therapy
Clareo Health | HER2 and LA/mUC: A Multi-country Chart Review Cohort Study
